Triazavirin

Triazavirin is a nucleoside analogue of nucleic acid and an antiviral agent. Triazavirin works by inhibiting the synthesis of viral RNA and DNA and replication of genomic fragments. Triazavirin is also an effective protective agent on the transmission stage of influenza[1].

Product Specifications

CAS Number

[928659-17-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

DNA/RNA Synthesis; Influenza Virus; Nucleoside Antimetabolite/Analog

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/triazavirin.html

Purity

99.15

Solubility

DMSO : 125 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

Smiles

O=C1N([N-]C(SC)=N2)C2=NN=C1[N+]([O-])=O.[H]O[H].[H]O[H].[Na+]

Molecular Formula

C5H7N6NaO5S

Molecular Weight

286.20

Precautions

H302, H315, H319, H335

References & Citations

[1] Kozhikhova KV, et al. Preparation of chitosan-coated liposomes as a novel carrier system for the antiviral drug Triazavirin. Pharm Dev Technol. 2018 Apr;23 (4) :334-342.|[2]Loginova SIa, et al. Investigation of Triazavirin antiviral activity against tick-borne encephalitis pathogen in cell culture. Antibiot Khimioter. 2014;59 (1-2) :3-5.|[3]Loginova SY, et al. Investigation of Therapeutic Efficacy of Triazavirin Against Experimental Forest-Spring Encephalitis on Albino Mice. Antibiot Khimioter. 2015;60 (7-8) :11-3.